Defensible Scope Reduction in High-Stakes Pharmaceutical IP Litigation

Lineal partnered with a Fortune 100 pharmaceutical company to reduce review scope, cost, and risk in a complex IP litigation — applying governed analytics and AmplifyReview to eliminate unnecessary first-pass review while preserving defensibility.